Five things for pharma marketers to know: Thursday, February 11, 2016
1. Sales of Copaxone, Teva Pharmaceutical's multiple sclerosis therapy, fell 14% to $960 million in the fourth quarter of 2015, compared to the $1.4 billion it reported in the same period a year ago. The drugmaker attributed the decline to lower sales volume.
2. Mylan said it will acquire Meda AB, a Swedish drugmaker that markets products to treat respiratory conditions, pain and inflammation. The deal is worth $7.2 billion cash and stock. (AP)
3. Most health insurers that offered Affordable Care Act plans reported financial losses in 2015. The plans paid more for care than what they took in from premiums in the first three quarter of 2015. (WSJ)
4. Incyte said it will stop testing Jakafi, its best-selling blood cancer drug, as a treatment for solid tumor cancers. The drugmaker discontinued a late-stage clinical trial testing the drug in pancreatic cancer and two mid-stage trials for breast and lung cancers. (Reuters)
5. Imprimis Pharmaceuticals said it will produce a compounded version of Retrophin's kidney-stone drug, Thiola. Under the leadership of former Retrophin CEO Martin Shkreli, the company had raised the price of Thiola from $1.50 a tablet to $30 a tablet. (Reuters)